Current perspective on infections and mitigation strategies in primary systemic vasculitis-Reference-Cited by-同舟云学术

Current perspective on infections and mitigation strategies in primary systemic vasculitis

Published:2024-04-26 Issue:8 Volume:26 Page:279-289
ISSN:1523-3774
Container-title:Current Rheumatology Reports
language:en
Short-container-title:Curr Rheumatol Rep

Author:

Tumba Manuel Carpio,Silva Raisa Lomanto,Arevalo Ana B.,Sattui Sebastian E.^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11926-024-01149-6.pdf

Reference76 articles.

1. Kitching AR, Anders H-J, Basu N, Brouwer E, Gordon J, Jayne DR, et al. ANCA-associated vasculitis. Nat Rev Dis Primer. 2020;6:71. https://doi.org/10.1038/s41572-020-0204-y.

2. U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) v5.0 [Internet]. 2017 [cited 2024 Mar 30]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf.

3. Rathmann J, Jayne D, Segelmark M, Jönsson G, Mohammad AJ. Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. Rheumatol Oxf Engl. 2021;60:2745–54. https://doi.org/10.1093/rheumatology/keaa699.

4. Thomas K, Argyriou E, Kapsala N, Panagiotopoulos A, Chalkia A, Hadziyannis E, et al. Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients. Arthritis Res Ther. 2021;23:90. https://doi.org/10.1186/s13075-021-02452-8.

5. Therkildsen P, de Thurah A, Nielsen BD, Faurschou M, Baslund B, Hansen IT, et al. The one-year infection risk among patients diagnosed with giant cell arteritis: use of antibiotics and hospitalisations. Rheumatol Oxf Engl. 2024:keae107. https://doi.org/10.1093/rheumatology/keae107.